Yongli Dong

Yongli Dong is a Principal Scientist at AbbVie, with ongoing experience as Associate Director and Principal Scientist at BlueRock Therapeutics since January 2021. At BlueRock, Yongli Dong leads a pre-clinical team in developing humanized mouse models and assessing various cellular products for efficacy and safety in immune-oncology, autoimmune, and off-the-shelf projects. Previous roles include Senior Scientist at Astellas Pharma, where responsibilities involved preclinical study oversight and developing assays for stem cell-derived cellular products, and Project Leader at Precigen Inc., focusing on CAR-T cell development for autoimmune diseases. Prior experience includes an Associate Research Scientist position at Yale University, where Yongli Dong contributed to cancer immunotherapy research. Yongli Dong holds a Ph.D. in Immunology from Fudan University, earned in 2010.